ArticleMolecules (Basel, Switzerland)2020
In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2.
Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Rational Design of a Bioconjugated Antitumor Peptide with Tumor-Selective Targeting and Microenvironment-Responsive Activation.Pharmaceutical research · 2026Article
- Short-peptide-based enteral nutrition affects rats MDP translocation and protects against gut-lung injury via the PepT1-NOD2-beclin-1 pathway in vivo.Molecular biology reports · 2024Article
- MLASM: Machine learning based prediction of anticancer small molecules.Molecular diversity · 2024Article
- Characterization and Classification In Silico of Peptides with Dual Activity (Antimicrobial and Wound Healing).International journal of molecular sciences · 2023Article
- Mechanisms and regulation of defensins in host defense.Signal transduction and targeted therapy · 2023Review
- Expression of Human β-defensin 2 (hBD-2) in Pichia Pastoris and Investigation of Its Binding Efficiency with ACE-2.The protein journal · 2023Article
- Antimicrobial Peptides: Challenging Journey to the Pharmaceutical, Biomedical, and Cosmeceutical Use.International journal of molecular sciences · 2023Review
- Advances in Antimicrobial Peptide Discovery via Machine Learning and Delivery via Nanotechnology.Microorganisms · 2023Review
- Antimicrobial Peptides-Mechanisms of Action, Antimicrobial Effects and Clinical Applications.Antibiotics (Basel, Switzerland) · 2022Review
- Anurans against SARS-CoV-2: A review of the potential antiviral action of anurans cutaneous peptides.Virus research · 2022Review
- New Advances in Short Peptides: Looking Forward.Molecules (Basel, Switzerland) · 2022Article
- Antimicrobial Mechanisms and Clinical Application Prospects of Antimicrobial Peptides.Molecules (Basel, Switzerland) · 2022Review
- Advances in Research of Short Peptides.Molecules (Basel, Switzerland) · 2022Article
- dbAMP 2.0: updated resource for antimicrobial peptides with an enhanced scanning method for genomic and proteomic data.Nucleic acids research · 2022Article
- Defensins: Therapeutic molecules with potential to treat SARS-CoV-2 infection.The Indian journal of medical research · 2022Article
- Caerin 1 Peptides, the Potential Jack-of-All-Trades for the Multiple Antibiotic-Resistant Bacterial Infection Treatment and Cancer Immunotherapy.BioMed research international · 2022Review
- Brevinin-2GHk, a Peptide Derived from the Skin ofViruses · 2021Article
- Antimicrobial Peptides: A Potent Alternative to Antibiotics.Antibiotics (Basel, Switzerland) · 2021Review
- A Fungal Defensin Targets the SARS-CoV-2 Spike Receptor-Binding Domain.Journal of fungi (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A serious pandemic has been caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The interaction between spike surface viral protein (Sgp) and the angiotensin-converting enzyme 2 (ACE2) cellular receptor is essential to understand the SARS-CoV-2 infectivity and pathogenicity. Currently, no drugs are available to treat the infection caused by this coronavirus and the use of antimicrobial peptides (AMPs) may be a promising alternative therapeutic strategy to control SARS-CoV-2. In this study, we investigated the in silico interaction of AMPs with viral structural proteins and host cell receptors. We screened the antimicrobial peptide database (APD3) and selected 15 peptides based on their physicochemical and antiviral properties. The interactions of AMPs with Sgp and ACE2 were performed by docking analysis. The results revealed that two amphibian AMPs, caerin 1.6 and caerin 1.10, had the highest affinity for Sgp proteins while interaction with the ACE2 receptor was reduced. The effective AMPs interacted particularly with Arg995 located in the S2 subunits of Sgp, which is key subunit that plays an essential role in viral fusion and entry into the host cell through ACE2. Given these computational findings, new potentially effective AMPs with antiviral properties for SARS-CoV-2 were identified, but they need experimental validation for their therapeutic effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.